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Abstract
Most cervical cancer deaths in Finland occur after the termination of the national screening
program, targeted at women aged 30 to 64 years. The purpose of this study was to examine
the effectiveness of screening at age 65 in reducing cervical cancer mortality. A register-
based cohort study was performed with a follow-up period between 1991 and 2014. Mortal-
ity risk ratios for incident cervical cancer cases diagnosed at age 65 or older were compared
between women invited and not invited for screening. The background risk difference
between the studied areas was accounted for by using a reference cohort. The relative risk
of death for women invited for cervical cancer screening at the age of 65 was 0.52 (95% CI:
0.29–0.94). The relative risks for women not attending and attending to screening with
respect to the uninvited were 1.28 (CI: 0.65–2.50) and 0.28 (CI: 0.13–0.59), respectively.
Inviting 65-year-old women for screening has been effective in reducing cervical cancer
mortality.
Introduction
There is no clear evidence on the appropriate age at which to stop screening for cervical cancer
[1]. The organized cervical cancer screening program in Finland, mainly targeted to women
aged 30–64 years, has been shown to be the most effective among women above the age of 40
[2]. However, an increasing number of studies have suggested that screening also women aged
65 and older reduces cancer incidence and mortality [3–5].
Cervical cancer is caused by the human papillomavirus (HPV) infection, and the probabil-
ity of acquiring a new infection is the highest at a young age [6]. The decreasing HPV-preva-
lence by age is often considered to justify the discontinuation of screening older women.
Cervical cancer incidence is also relatively small in elderly women with a history of negative
screening results. Castañón et al. demonstrated that stopping the screening of women with, for
example, three or more consecutive negative screening results before age 65 could be safe [7].
However, it has also been demonstrated that the risk for cervical cancer after consecutive negative
screening results is similar for women aged 50 and for women of younger ages [8]. Therefore, a
history of negative results at an older age might not be a sufficient reason to stop screening.
The growing life expectancy is likely to effect the future of cervical cancer burden among
the elderly. Although cervical cancers are relatively rare among older women who have been
offered screening earlier in life, they tend to be more severe with a poorer prognosis compared
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to cancers among the young [9]. Thus, early detection of cancers in the older population
would be beneficial, reducing disease burden and mortality.
The aim of this study was to determine whether inviting women aged 65 to screening is
associated with reduced mortality from cervical cancer.
Materials and methods
The national target age for cervical cancer screening in Finland is 30–60, which corresponds to
the minimum target age range recommended by the European screening guidelines [1].
Screening invitations are sent every five years to women in the target age range. Follow-up
screening 1–2 years after the routine screen is recommended for women with mild abnormali-
ties. These screenings continue until the next screening round (or age 64) if necessary. The
screening test is mostly conventional cytology. However, primary HPV testing with a cytology
triage was used in some areas as a part of a randomized trial in 2003–2012 [10]. Since 2012,
primary HPV testing has been incorporated into the cervical cancer screening program in an
increasing number of areas [11].
Individual municipalities are responsible for the screening organization and the majority of
them stop screening at the minimum required age of 60. However, some municipalities con-
tinue inviting women until age 65. The capital city of Helsinki has invited all 65-year-old
women regularly since 1991 [12]. This enabled us to study the effectiveness of screening at age
65 by comparing women invited to screening in Helsinki to those who were not invited else-
where. The invited population was limited to Helsinki only since the background risk of cervi-
cal cancer was considerably higher in the capital city, also among the older age groups [13]. In
addition, only 20% of the invited women were living outside Helsinki, and they were allocated
sparsely and invited irregularly during the follow-up. Thus, the invited women were all resi-
dents of Helsinki, whereas the uninvited were all from other parts of the country.
We performed a population-based cohort study with a follow-up period in 1991–2014. A
cohort of approximately one million women born in 1926–1956 and aged 55–65 at the begin-
ning of the follow-up was derived from the population registry. Cervical cancer diagnoses and
deaths from incident cases in women aged 55 and older until the year 2014 were linked from
the cancer registry. The cohort’s screening records from 1991–2011 were then linked from the
Mass Screening Registry.
Data on deaths due to cases diagnosed at age 55–64 were used to assess the background risk
difference between Helsinki and the comparison regions (a reference cohort of women born in
1936–1956, N = 773,171). We considered ten years as an appropriate minimum time for the
cancer incidence follow-up. Deaths from incident cases at age 65 years or older were used to
assess the association between an invitation at age 65 and cervical cancer mortality (a study
cohort of women born in 1926–1946, N = 611,100). An individual woman might have contrib-
uted to both the study and reference cohorts. The research data are illustrated in Fig 1. After
exclusions e.g. due to previous cervical cancers and missing screening data, we ended up with
a total cohort of 954,128 women. Data exclusions are shown in more detail in Fig 2.
We estimated the incidence-based mortality risk ratio of cervical cancer for women invited
to routine screening at the age of 65 compared to those not invited. The risk ratio was calcu-
lated using Poisson regression. Person-years (median = 11.1) were recorded until death, emi-
gration or end of follow-up period. An interaction term between the cohort indicator (study
vs. reference cohort) and the residential area was included in the model. The term provided us
with a background risk adjusted effectiveness estimate of invitation at age 65 in the study
cohort. Risk ratios were also estimated for attending and non-attending women with respect
to the uninvited.
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Results
Of the women in the study cohort, 11% lived in Helsinki and received an invitation for routine
screening at the age of 65 and around 75% of them attended. In the reference cohort, around
12% lived in the city of Helsinki at the beginning of the follow-up (Table 1). Among these
women, the risk of death from cervical cancer was elevated (RR = 1.91, 95% CI: 1.25–2.92),
compared to those living in municipalities not inviting 65-year-olds. This estimate was consid-
ered as a measure of the geographical background risk difference between Helsinki and the
areas not inviting age 65.
The background risk adjusted relative risk of death from cervical cancer for women invited
at the age of 65 was 0.52 (95% CI: 0.29–0.94), compared to the uninvited. The relative risks for
women not attending and attending to screening with respect to the uninvited were 1.28 (95%
CI: 0.65–2.50) and 0.28 (95% CI: 0.13–0.59), respectively (Table 2).
Descriptive results on the screening history before age 65 among women in the study
cohort are presented in Table 3. The crude mortality rate for cervical cancer deaths diagnosed
after age 65 was lower for women attending to screening at ages 55–64 compared to non-
attending women or women without available information on previous screening history. In
Fig 1. Illustration of the events and person-years in the study and reference cohorts. In the reference cohort,
cervical cancer (CxCa) deaths after age 55 were considered for incident cancer cases diagnosed at ages 55–64. In the
study cohort, CxCa deaths were considered for incident cancer cases diagnosed at age 65 or older.
https://doi.org/10.1371/journal.pone.0214486.g001
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Helsinki, where also 65-year-olds were invited, a larger proportion of women had been
screened at ages 55–64 compared to the rest of the country. The mortality rate was higher also
among previously screened women (2.4 vs. 1.6), although number of cases was relatively small.
Out of all 237 cervical cancer deaths in the study cohort, 76 (32%) were due to adenocarci-
nomas. Other cancer types are shown in Table 4.
Fig 2. Exclusions from the total cohort, including the study and reference cohorts. An individual woman might have contributed to both the
study and reference cohorts. Follow-up between 1991 and 2014.
https://doi.org/10.1371/journal.pone.0214486.g002
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Discussion
We observed an almost 50% reduction in cervical cancer mortality among women invited to
screening in the city of Helsinki at age 65 compared to the uninvited women living elsewhere.
For attendees, the corresponding mortality reduction was over 70%. However, a part of the
result among the attendees is explained by self-selection, that is, the selection of women in the
screened group who are already at lower risk of cervical cancer. Women who did not attend
had an elevated risk of cervical cancer compared to the uninvited. Therefore, screening at age
65 might be even more effective if we were able to improve the attendance rate.
The challenge was to account for the different background risks between the capital city of
Helsinki and the municipalities not inviting 65-year-olds. Helsinki had a more extensive
screening target age group (25–65) during the entire follow-up but also the highest back-
ground risk of cervical cancer. In many high income countries, cervical cancer risk has found
to be elevated in urban areas [15,16]. Therefore, the wider target age range of cervical cancer
screening in Helsinki has undoubtedly been beneficial in terms of mortality reduction,
although the unadjusted differences between the invited and uninvited women were obscured
by the higher background risk compared to the rest of the country. Our descriptive results
indicated that the risk of death from cervical cancer after age 65 was higher in Helsinki also
among women who had been screened at ages 55–64.
Table 1. Characteristics and unadjusted cervical cancer mortality rates (per 100,000 person-years) by invitational status / residential area in the study and reference
cohorts.
Study cohort: women born in 1926–1946 N (%) Birth year (mean) CxCa deathsa 100 000 Person-years Rate per 100 000
All at age 65 545,934 (100) 1937.2 237 62.3 3.8
Not invited 486,869 (89) 1937.1 212 55.7 3.8
Invited (Helsinki) 59,065 (11) 1937.3 25 6.6 3.8
Did not attend 15,054 (3) 1936.8 15 1.6 9.3
Attendedc 44,011 (8) 1937.4 10 5.0 2.0
Reference cohort cohort: women born in 1936–1956 N (%) Birth year (mean) CxCa deathsb 100 000 Person-years Rate per 100 000
All at age 55 682,222 (100) 1947.5 130 81.7 1.6
Lived in a munic. which did not invite age 65 600,937 (88) 1947.5 103 71.9 1.4
Lived in a munic. which invited age 65 81,285 (12) 1947.1 27 9.9 2.7
CxCa, cervical cancer; munic., municipality.
a Deaths for cervical cancers diagnosed at age 65 or older.
b Deaths for cervical cancers diagnosed at ages 55–64.
c Attendance rate 75%.
https://doi.org/10.1371/journal.pone.0214486.t001
Table 2. Poisson model estimates for the effect of screening invitation in Helsinki and attendance at age 65 on cer-
vical cancer mortality.
crude RRa adjusted RRb
Not invited 1 1
Invited 1.00 (0.66–1.51) 0.52 (0.29–0.94)
Did not attend 2.44 (1.45–4.12) 1.28 (0.65–2.50)
Attended 0.51 (0.27–0.96) 0.28 (0.13–0.59)
a Only study cohort analysed.
b Study and reference cohorts combined and risk ratios adjusted for the background risk difference between the
areas.
https://doi.org/10.1371/journal.pone.0214486.t002
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A relatively high percentage of the deaths in the study cohort were due to adenocarcinomas.
In the future, HPV testing might be especially useful for detecting adenocarcinomas, which are
less likely to be prevented by conventional cytology [17]. Only a minority of the Finnish
municipalities are currently using HPV testing as the primary screening method. During the
study period, also Helsinki was mostly using cytology screening. However, HPV based screen-
ing is now becoming more widespread, and is being introduced in Helsinki in 2019. It will be
interesting to see whether this will have an effect on cervical cancer mortality, specifically on
deaths due to adenocarcinoma.
This was the first time that the effectiveness of screening at age 65 was studied in Finland
using longitudinal cohort data with an extensive follow-up time of 24 years. Since we com-
pared the invited women to the uninvited, we were able to see the impact of screening at the
population level without having to tackle the problem of self-selection bias. Statistical power
was, however, somewhat limited due to the rareness of cervical cancer deaths and the relatively
small proportion of women invited in the oldest age group. However, our results are in line
with previous studies reporting reduced mortality rates for women screened until the age of
69. An earlier case-control study from Finland found a long-lasting protective effect of screen-
ing at ages 55–69 and a strong indication of additional benefit from extending the upper age to
65 [4]. Similar results were also reported for example in studies from the US and Canada [3,5].
A nationwide extension of the upper age of screening would also be cost-effective. An earlier
modelling study showed that screening until age 70 was cost-effective with 8450 euros per
QALY [18].
Cervical cancer incidence has decreased substantially in Finland after the beginning of
screening in the early 1960s [19]. Since then, the decreasing trend has been consistent among
older ages due to the ever-increasing number of older women having been exposed to screen-
ing. The higher incidence at an older age could at least partly be explained by the screening
Table 3. Characteristics and unadjusted cervical cancer mortality rates (per 100,000 person-years) by invitational status at age 65 and screening history at ages 55–
64 in the study cohort.
Study cohort: women born in 1926–1946 N (%) Birth year (mean) CxCa deathsa 100 000 Person-years Rate per 100 000
Not invited at age 65 486,869 (100) 1937.1 212 55.7 3.8
Not screened at 55–64 122,926 (25) 1937.5 72 14.1 5.1
Screened at 55–64 252,750 (52) 1940.8 36 22.0 1.6
Screening history not known 111,193 (23) 1928.5 104 19.7 5.3
Invited at age 65 (Helsinki) 59,065 (100) 1937.3 25 6.6 3.8
Not screened at 55–64 9,525 (16) 1938.5 5 1.0 5.2
Screened at 55–64 36,658 (62) 1940.0 8 3.4 2.4
Screening history not known 12,882 (22) 1928.5 12 2.2 5.4
CxCa, cervical cancer
a Deaths for cancers diagnosed at age 65 or older.
https://doi.org/10.1371/journal.pone.0214486.t003
Table 4. Cancer types in the study cohort for cancers diagnosed at age 65 or older (N = 237).
Study cohort: women born in 1926–1946 N (%)
Squamous cell carcinoma 130 (55)
Adenocarcinoma 76 (32)
Carcinoma other or unspecified 24 (10)
Other 7 (3)
https://doi.org/10.1371/journal.pone.0214486.t004
Effectiveness of cervical cancer screening at age 65
PLOS ONE | https://doi.org/10.1371/journal.pone.0214486 March 26, 2019 6 / 9
histories of the oldest birth cohorts [20,21]. In the study cohort the oldest women had their
first screen around the age of 40 in the late 1960s, and thus had a smaller number of lifetime
screens than the younger women. It is safe to assume that all women in our cohort have been
subjected to a similar screening policy at least since their 40s or 50s. Even so, it remains to be
seen whether the incidence and mortality of women over the age of 65 will be different in the
future when the lifetime screening histories will be more similar across birth cohorts.
The hysterectomy prevalence was presumably quite high in our study cohort. Unfortu-
nately, we were not able to have individual-level data on hysterectomies in this study. Luoto
et al. (2004) estimated that approximately one-fifth of women aged 45–64 have undergone a
hysterectomy in Finland. A peak in the rate was observed in the birth cohort born in 1943–47,
after which it started to decline [22]. However, it is unlikely that the hysterectomy prevalence
has differed significantly between Helsinki and the rest of the country, thanks to the unified
current care guidelines since 1994 [23]. Even if differences existed, we assume that our model
takes also this into account.
In this study, only tests taken within the organized screening program were available for
analysis. Salo et al. (2014) estimated that the overall five-year coverage of Pap tests in Finland
is as high as 87%, when also tests outside the organized program are taken into account. These
opportunistic tests are taken especially from young women or women who are within the tar-
get age range of the program. The overall test coverage decreases substantially at older ages,
after the termination of the program, when also the opportunistic testing is reduced [24].
However, if in Helsinki women of older ages would have had opportunistic tests more fre-
quently than in other parts of the country, it could have also explained some part of the mortal-
ity difference. Incorporating also opportunistic data would be an asset in the future.
In 2017 the average life-expectancy of a Finnish woman at birth was approximately 84
years, and 24 percent of the female population was aged 65 and older [25,26]. The relative size
of the older population has grown over the more recent years across the world, as well as the
prevalence of cervical cancer risk factors, such as increased sexual activity [27,28]. At the
moment most of the deaths from cervical cancer in Finland occur after the last screening invi-
tation [4], when also Pap testing outside the organized program decreases substantially. There-
fore, it is likely that the cervical cancer burden among the older population will not lessen in
the near future.
To conclude, our analysis showed a significant cervical cancer mortality reduction among
women invited for screening in Helsinki at the age of 65. The extension of the organized
screening program to an older age in the capital city has thus been beneficial. These results
could be generalizable to other countries and regions with long-standing and good-quality
screening programs. Several studies have already confirmed the increased risk of cervical can-
cer in older women with earlier abnormal or unavailable screening results [29–31]. Therefore,
the continuation of screening for cervical cancer until a sufficiently old age should be ensured.
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Formal analysis: Maiju Pankakoski, Ahti Anttila, Sirpa Heinävaara.
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